Cardiology News In Brief
This article was originally published in The Gray Sheet
Executive Summary
Heart CARE for diabetics: Updated results from Medtronic's 813-patient CARE-HF study finds Medtronic's cardiac resynchronization therapy (CRT) is equally effective for diabetic and nondiabetic heart failure patients. CRT reduced the all-cause mortality rate in diabetic patients by 39%, compared with a 40% reduction in nondiabetics, the firm reported Sept. 3 at the European Society of Cardiology/World Congress of Cardiology 2006 meeting in Barcelona. Overall, Medtronic's InSync CRT products reduced the risk of heart failure death by 45% and sudden cardiac death by 53% in the study, which randomized patients to medical management with and without CRT, with an average follow-up period of about 36 months (1"The Gray Sheet" March 14, 2005, p. 7)...
You may also be interested in...
J&J Gains Next-Gen CoStar Stent Through $1.4 Bil. Conor Purchase
Johnson & Johnson hopes that its $1.4 bil. purchase of next-generation drug-eluting stent developer Conor Medsystems will help it retain top-tier market share as a flurry of new competitors joins the market
J&J Gains Next-Gen CoStar Stent Through $1.4 Bil. Conor Purchase
Johnson & Johnson hopes that its $1.4 bil. purchase of next-generation drug-eluting stent developer Conor Medsystems will help it retain top-tier market share as a flurry of new competitors joins the market
Conor Ramps Up Production Of CoStar Stent To Prep For U.S. Launch
Conor Medsystems is already boosting manufacturing capacity in preparation for the U.S. launch of its CoStar drug-eluting stent, though the product is not slated to hit the market until late next year at the earliest